TY - JOUR
T1 - Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat
AU - Davis, Jeremy
AU - Higginbotham, Allan
AU - O'Connor, Timothy
AU - Moustaid-Moussa, Naima
AU - Tebbe, Adam
AU - Kim, Young Cheul
AU - Cho, Kae Won
AU - Shay, Neil
AU - Adler, Stuart
AU - Peterson, Richard
AU - Banz, William
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/4
Y1 - 2007/4
N2 - Background/Aims: Previously, we demonstrated that soy protein ameliorates the diabetic phenotype in several rodent models of obesity and metabolic syndrome (MS). This study was designed to further elucidate factors related to adiposity, glycemic control, and renal function in male Zucker Diabetic Fatty (ZDF/Leprfa) rats. Methods: Animals were randomly assigned to one of four diets: control, casein (C); low isoflavone (LIS) soy protein; high isoflavone (HIS) soy protein, or casein + rosiglitazone (CR) for 11 weeks. At sacrifice, physiological, biochemical, and molecular parameters were determined. Results: Body weight and total adiposity were higher in LIS and CR diet groups despite lower food intake. Additionally, these animals exhibited differential regulation of adipose-specific proteins (PPAR-γ and GLUT4) and enzyme activity (FAS and GPDH). HIS-fed animals had reduced total and liver adiposity. Glycemic control was prolonged in both soy-based and rosiglitazone (RGZ) groups. Renal dysfunction was significantly reduced in soy-fed and RGZ-treated rodents as demonstrated by lower levels of proteinuria and dilated tubules with proteinaceous casts. Conclusion: Collectively, these data provide evidence that soy protein with low or high isoflavone content may have therapeutic significance in reducing severity of diabetes, MS, and renal disease as demonstrated in this preclinical model.
AB - Background/Aims: Previously, we demonstrated that soy protein ameliorates the diabetic phenotype in several rodent models of obesity and metabolic syndrome (MS). This study was designed to further elucidate factors related to adiposity, glycemic control, and renal function in male Zucker Diabetic Fatty (ZDF/Leprfa) rats. Methods: Animals were randomly assigned to one of four diets: control, casein (C); low isoflavone (LIS) soy protein; high isoflavone (HIS) soy protein, or casein + rosiglitazone (CR) for 11 weeks. At sacrifice, physiological, biochemical, and molecular parameters were determined. Results: Body weight and total adiposity were higher in LIS and CR diet groups despite lower food intake. Additionally, these animals exhibited differential regulation of adipose-specific proteins (PPAR-γ and GLUT4) and enzyme activity (FAS and GPDH). HIS-fed animals had reduced total and liver adiposity. Glycemic control was prolonged in both soy-based and rosiglitazone (RGZ) groups. Renal dysfunction was significantly reduced in soy-fed and RGZ-treated rodents as demonstrated by lower levels of proteinuria and dilated tubules with proteinaceous casts. Conclusion: Collectively, these data provide evidence that soy protein with low or high isoflavone content may have therapeutic significance in reducing severity of diabetes, MS, and renal disease as demonstrated in this preclinical model.
KW - Adiposity
KW - Isoflavone content
KW - Metabolic syndrome
KW - Soy protein
KW - Zucker Diabetic Fatty rats
UR - http://www.scopus.com/inward/record.url?scp=34247339685&partnerID=8YFLogxK
U2 - 10.1159/000100820
DO - 10.1159/000100820
M3 - Article
C2 - 17356265
AN - SCOPUS:34247339685
VL - 51
SP - 42
EP - 52
JO - Annals of Nutrition and Metabolism
JF - Annals of Nutrition and Metabolism
SN - 0250-6807
IS - 1
ER -